Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: cisatracurium besylate

« Back to Dashboard
Cisatracurium besylate is the generic ingredient in four branded drugs marketed by Fresenius Kabi Usa, Sandoz Inc, and Abbvie, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for cisatracurium besylate. One supplier is listed for this compound.

Summary for Generic Name: cisatracurium besylate

Drug Master File Entries: see list8
Suppliers / Packaging: see list3

Pharmacology for Ingredient: cisatracurium besylate

Clinical Trials for: cisatracurium besylate

Optimal Dose of Combination of Rocuronium and Cisatracurium
Status: Completed Condition: Chronic Otitis Media; Anesthesia

Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia
Status: Completed Condition: Fasciculation

Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis
Status: Not yet recruiting Condition: C.Delivery; Surgery (Previous), Gynecological

Study of Cisatracurium and Sufentanil Consumption Using a Closed Loop Computer Control Infusion System
Status: Recruiting Condition: The Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index.; Effect of Dexmedetomidine on Sufentanil Consumption.; Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age Groups.

Effects of Cisatracurium on Sccinylcholine-induced Fasciculations
Status: Completed Condition: Fasciculations

Gender and PK-PD of Propofol and Cisatracurium
Status: Completed Condition: Gender

Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia
Status: Completed Condition: Postoperative Residual Curarization; Residual Neuromuscular Block

Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia
Status: Completed Condition: Intraocular Pressure

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc
cisatracurium besylate
INJECTABLE;INJECTION200154-002Feb 3, 2012RXNo<disabled><disabled>
Sandoz Inc
cisatracurium besylate
INJECTABLE;INJECTION200159-001Feb 3, 2012RXNo<disabled><disabled>
Fresenius Kabi Usa
cisatracurium besylate
INJECTABLE;INJECTION203182-001Feb 26, 2015RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn